Shenzhen University General Hospital
July
Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
Dual-target CAR-T Cells
B ALL
Relapse
Refractory B Acute Lymphoblastic Leukemia
Dual target CAR-T cell therapy
PHASE1
PHASE2
Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Strictly follow the inclusion criteria to screen eligible subjects for inclusion in clinical trials. The selected patients received CD19/CD22 dual-target CAR-T cell therapy. After the treatment is over, follow-up regularly to determine the survival status and follow-up treatment.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 20 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | Clinical Trial of CD19/CD22 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia |
Actual Study Start Date : | 2020-10-20 |
Estimated Primary Completion Date : | 2022-12-31 |
Estimated Study Completion Date : | 2022-12-31 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 14 Years to 75 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Shenzhen University General hospital
Shenzhen, Guangdong, China, 518055